An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CD19 Autologous CAR T-cells Produced by Rapid Personalized Manufacture (RPM CD19-mbIL15-CAR-T Cell Infusion) in Patients With Relapsed/Refractory B-cell Malignancies
Latest Information Update: 05 Aug 2020
At a glance
- Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapy-TriArm-Therapeutics (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Aug 2020 New trial record